JPRN-UMIN000005985
Completed
未知
A Randomized Placebo-controlled Trial of an Early Interventional Treatment with Mometasone Furoate Nasal Spray in Japanese Cedar/Cypress Pollinosis - Effect of EIT with mometasone on JCCP
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences0 sites50 target enrollmentJuly 16, 2011
ConditionsJapanese cedar/cypress pollinosis
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Japanese cedar/cypress pollinosis
- Sponsor
- Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(a) concomitant sinonasal disease affecting the outcomes of this trial (e.g. nasal polyps, rhinosinusitis, nasal septum deviation); (b) concomitant treatment\-requiring allergic rhinitis caused by allergens other than Japanese cedar/cypress pollen; (c) rhinitis medicamentosa and non\-infectious, non\-allergic rhinitis; (d) cedar pollen\-specific immunotherapy; (e) sinonasal surgery including laser vaporization of inferior turbinates within 1 year; (f) medication with anti\-allergic drugs including antihistamines, chromons, glucocorticoids and decongentants within 2 weeks; (g) hypersensitivity to MFNS; (h) systemic infection including mycosis; (i) pregnancy and breastfeeding.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Research study for early treatment of Patent Ductus Arteriosus, placebo against paracetamol in extremely low birth weight infants (ETAPA)EUCTR2020-004245-37-IEniversity College Dublin218
Active, not recruiting
Phase 1
Research study for early treatment of Patent Ductus Arteriosus, placebo against paracetamol in extremely low birth weight infants (ETAPA)Patent Ductus ArteriosusMedDRA version: 20.0Level: PTClassification code 10034130Term: Patent ductus arteriosusSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]EUCTR2020-004245-37-CZniversity College Dublin218
Completed
Not Applicable
A Phase 1, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses Oral Doses of APX001, to Investigate the Effect of Food on APX001 and to Investigate the Drug-Drug Interaction Potential of APX001NL-OMON45345Amplyx Pharmaceuticals, Inc.46
Completed
Not Applicable
A phase 1, randomized, placebo-controlled study to assess the safety and pharmacokinetics of multiple ascending dose regimens of TP-6076.Infecties.Infections.NL-OMON45496Tetraphase Pharmaceuticals, Inc.56
Active, not recruiting
Phase 2
This is a Clinical Trial to Assess if the Coded Ayurvedic Drug AYUSH D brings the Blood Sugar under Control in Prediabetic SubjectsCTRI/2017/11/010716Incharge